Key Takeaways
- U.S. reset underway, not a surprise: U.S. revenue fell 13.4% QoQ on constant currency basis as Tolvaptan competition intensified and Mirabegron LOE played out, exactly as management had telegraphed. The base business and new launches are already filling the gap.
- Gross margins held the line: At 74.2%, down only 40 bps QoQ despite the U.S. headwinds, because mix improvement in other regions and forex tailwinds absorbed the Tolvaptan and Mirabegron pricing pressure.
- India chronic engine is accelerating: Chronic therapies grew 19.5%, diabetes surged 25%+ on Huminsulin® leadership and the Semaglutide launch, and the chronic share target has been raised to ~70% over five years.
- FY28 is an investment year, not a growth year: Management is building the specialty, biosimilar and 505(b)(2) pipeline while absorbing further Tolvaptan erosion and Mirabegron competition post-September, explicitly calling FY28 a period of consolidation before margins could re-expand toward 29–30% in FY29–30.
- What to watch next quarter: Whether the promised H2 organic growth of ~20% ex-U.S. materializes, the pace of Tolvaptan's further competitive erosion, and any update on Apixaban Oral Suspension market access build-out ahead of its FY28 launch.
U.S. Business: The Tolvaptan Reset & What Comes Next
- The Tolvaptan unwind: Two additional generic entrants drove the QoQ revenue decline; management expects competitive intensity to increase further with the possibility of more entrants, and both margin and revenue contribution are expected to come down significantly over coming quarters.
- Mirabegron holding steady: The product has been relatively stable; the decline is primarily concentrated in Tolvaptan, not a broad-based U.S. portfolio problem.
- FY27 U.S. revenue intact: Management continues to expect USD 1.1 bn to USD 1.2 bn, with growth in the base business, new injectable launches, and Pegfilgrastim contributions offsetting the Tolvaptan and Mirabegron impact.
- FY28 floor at USD 1 bn plus: Revenue should remain above that bar despite additional Tolvaptan competition and Mirabegron competition post-September next year, supported by Apixaban, Dalbavancin, and biosimilars led by Pegfilgrastim.
- FY29 durability: Management expects to maintain the USD 1 bn run rate with help from specialty, complex injectables, and respiratory products, as the full-year impact of durable pipeline products drives growth.
- The pipeline math: On track to file more than 15 products this fiscal year, with over 60 launches expected over the next three years including ~25 injectable and respiratory products, 5 biosimilars, and 2–3 505(b)(2) products.
Vinita Gupta: "Revenue should remain at a billion dollars plus, which is a bar that we want to be able to maintain."
Apixaban Oral Suspension: The Next Big Bet
- The product: Tentative approval received through the 505(b)(2) pathway during the quarter; launch expected in FY28, with a build-up over months and quarters.
- The market: The overall Apixaban brand is a USD 10-plus billion market; Lupin is targeting specific channels where the liquid dosage form benefits patients, not a direct B2C play, which management believes would have been aspirational with limited time before generics enter in FY29.
- Post-generic tail: Management expects to retain some share even after generics enter in FY29, especially in channels where the oral suspension form factor matters, and hopes to have a tail in the coming years.
- Margins: Expected to be attractive, like an exclusive product, but with some commercial investment required for market access and channel expertise over the next couple of quarters.
- Manufacturing and strategy: Filed from the Somerset facility with enough capacity to meet an upside scenario; management evaluated all partnering options and believes in a strong internal commercial strategy.
- Addressable market unanswered: When asked for the specific addressable market size, management said only that "certain channels" represent a good percentage of the market, without quantifying the figure.
India Formulations: Chronic Share Ambition Keeps Rising
- Core growth: The prescription business grew 13.8% aided by volume growth of 6%; chronic therapies grew 19.5%, well ahead of IPM.
- Diabetes dominance: The segment delivered 25%+ YoY growth, led by market leadership in Huminsulin® and the successful launch of Semaglutide injection, where Lupin is the third-largest generic.
- H1 vs. target: H1 growth ran at 1.16x IPM, below the 1.2x–1.3x goal, because respiratory (inhalation side: MDI, DPI, nebulization) saw very slow growth and cardiac slowed somewhat. Management expects a respiratory pickup in H2, noting that inhalation growth alternates years with no clear pattern.
- Chronic share target raised: The aim is to increase chronic share to ~70% over the next five years from ~66% currently, but management explicitly says that is not a ceiling and chronic share is expected to keep growing.
- Novel products ambition: The target is for novel proprietary products to contribute one-third of India revenues within the next 10 years, built through in-house development and in-licensing.
- Sales force and pipeline: Supported by ~11,400 sales force and a pipeline of more than 80 new product launches over coming years.
Nilesh Gupta: "I would love to prove you wrong. Our plans add up to around 70%, but that does not mean we stop there. We are a chronic story and that is where growth will come from."
Margins: Holding the Line Today, Investing for Tomorrow
- Gross margin resilience: At 74.2%, down only 40 bps QoQ from 74.6%, because the Tolvaptan revenue decline was offset by mix change in other regions and forex tailwinds from forwards taken in Q1 at ~89–90 that had depressed Q1 realizations.
- FY27 EBITDA guidance maintained: Management remains committed to around 24–25%, while recognizing margins are likely to moderate in coming quarters due to intensifying U.S. competition, increased R&D investment, and higher input costs from Middle East macroeconomic challenges.
- Expenditure drivers: Employee expenses rose 29% YoY on regular annual increments and business growth; manufacturing and other expenses rose 23% YoY on higher volumes, field force expansion, and settlement-related costs on Mirabegron that will reverse.
- IT and AI investment phase: Spending on IT platforms and AI is elevated over the next few quarters; as a percentage of sales, it is expected to be much lower over 3–4 years, with outcomes visible across other lines.
- Longer-term margin path: Management sees a path back to 29–30% EBITDA margins in the FY29–30 timeframe as 505(b)(2)s, biosimilars, and specialty products scale, with FY28 potentially a period of consolidation.
Ramesh Swaminathan: "It is clearly because of that in the Americas, but there is a mix change in other parts. Moreover, there have been tailwinds in terms of forex associated with the impact on gross margins..."
Pipeline & Portfolio Evolution: Building Durability
- Respiratory complex generics: Exhibit batches for Spiriva Respimat® are done with filing expected this fiscal year; the Breo Ellipta product is making good progress with filing expected later this fiscal year, possibly slipping a couple of months into Q1 FY28. The broader MDI/Respimat/Ellipta portfolio of 7–8 products remains on track to be filed within this fiscal year or within a couple of months of year-end.
- Biosimilars ramp: Preparing to file 4–5 biosimilars for the U.S. over the next few years; Pegfilgrastim has already launched through partner Valorum. Management notes the marketplace is significantly more open today than 5–8 years ago, but pricing erosion and discounting by manufacturers do not help much, so the focus must be on payer incentives that drive substitution.
- Near-term injectable opportunities: Risperdal Consta®, Sugammadex (already launched, described as a nice opportunity), and Dalbavancin (both 505(b)(2) and generic) are attractive near-term drivers.
- Etanercept: U.S. filing expected later this fiscal year, targeting the first wave in 2029.
- Peptides: Glucagon and Liraglutide will continue to be material over the next couple of years; semaglutide and newer GLP-1s are not expected soon due to patent expiry beyond five years.
- Ophthalmic entry: The company has entered the space and is looking to grow across the globe, with the exclusive licensing partnership for Yuvezzi™ in Europe as an early move.
Vinita Gupta: "Investments in areas like specialty, particularly in Europe, as well as biosimilars and 505(b)(2)s, give us confidence that we should be able to evolve our developed markets business toward a more durable and sustainable portfolio, as opposed to one-off exclusives."
Regional & Other Performance
| Region | Trend | Commentary |
|---|---|---|
| Other Developed Markets | ▲ Strong | 46% YoY growth led by strong sales in Australia, Canada, and Europe; Europe delivered double-digit growth even without VISUfarma contribution. |
| Emerging Markets | ▼ Declined | 4% YoY de-growth with lower sales in Brazil, where Dapagliflozin faced additional competition after two years of strong upsides, offsetting double-digit growth in South Africa, Philippines, and Mexico. |
| VISUfarma acquisition | ▲ Closed | Contributing to Europe performance; the acquisition was a key driver of the net cash reduction from ₹4,636 crores to ₹3,349 crores, along with dividend payouts. |
| Gross margin tailwinds | ▲ Forex | Q2 benefited from forex tailwinds because forwards taken in Q1 at ~89–90 had depressed Q1 realizations; the unwind provided a sequential lift. |
| Other Operating Income | ▼ Lower | Declined ~81% YoY primarily due to lower export benefits from PLI schemes. |
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY27 U.S. revenue | USD 1.1 bn to USD 1.2 bn | FY27 |
| FY27 EBITDA margin | Around 24–25% | FY27 |
| H2 organic growth ex-U.S. | Around 20% | H2 FY27 |
| U.S. pipeline filings | More than 15 products | FY27 |
| U.S. launches | More than 60 products, including ~25 injectable/respiratory, 5 biosimilars, 2–3 505(b)(2)s | Next 3 years |
| Apixaban Oral Suspension launch | Q1 FY28 | FY28 |
| FY28 U.S. revenue floor | At least USD 1 bn plus | FY28 |
| FY29 U.S. revenue | Maintain USD 1 bn run rate | FY29 |
| India chronic share | ~70% | Next 5 years |
| India novel products share | One-third of India revenues | Next 10 years |
| India growth vs. IPM | 1.2x to 1.3x IPM growth rate | Ongoing |
| Full-year R&D spend | Around 8% of sales | FY27 |
| Full-year ETR | Around 27–28% | FY27 |
| Long-term EBITDA margin | 29–30% | FY29–30 timeframe |
| Spiriva Respimat® filing | This fiscal year | FY27 |
| Breo Ellipta filing | Later this fiscal year, possibly Q1 FY28 | FY27 / early FY28 |
| Etanercept U.S. filing | Later this fiscal year | FY27 |
| Biosimilar U.S. filings | 4–5 products | Next few years |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹7,827 cr, +11% YoY |
| U.S. sales | $317 million, -13.4% QoQ constant currency; +9.3% YoY |
| India formulations growth | 14.7% YoY; core prescription business +13.8% YoY |
| Other Developed Markets revenue | ₹1,182 cr, +46% YoY; 15% of total revenue |
| Emerging Markets growth | -4% YoY |
| API growth | ~20% YoY |
| Gross margin | 74.2%, vs 73.3% in Q2FY26 and 74.6% in Q1FY27 |
| EBITDA margin | 25.1%, vs 31.3% in Q2FY26; FY27 guidance of 24–25% |
| R&D spend | 7.9% of sales (₹618 cr); FY27 guidance ~8% |
| Employee benefit expenses | 18.3% of sales (₹1,424 cr), vs 16.2% in Q2FY26 |
| Manufacturing and other expenses | 31.3% of sales (₹2,438 cr), vs 29.0% in Q2FY26 |
| India chronic share | ~66% of portfolio in H1FY27, up from ~65% in FY26 |
| India chronic growth | 19.5% in H1FY27 vs IPM growth of 17.2% |
| India volume growth | 6.1% in H1FY27 |
| Net cash | ₹3,349 cr as of Sep 30, vs ₹4,636 cr on Mar 31, 2026 |
| Operating working capital | 87 days, vs 90 days in Q1FY27 |
| Effective tax rate | 28.5% in H1FY27; FY27 guidance 27–28% |
| U.S. FY27 revenue guidance | $1.1 bn – $1.2 bn; Q1 and Q2 above plan |
| U.S. FY28 revenue expectation | At least $1 bn |
| Tolvaptan market share | ~50% in recent months as sole generic |
| India prescription sales force | ~11,400 people |
| India H1FY27 outperformance vs IPM | ~1.16x (14.4% vs 14.3% IPM growth) |
| Diabetes segment growth | 25%+ YoY in Q2; third consecutive quarter of 20%+ growth |
| Anti-Diabetes segment outperformance | 1.5x category growth in H1FY27 |
| Cardiac segment outperformance | 1.1x category growth in H1FY27 |
| Dermatology segment outperformance | 1.5x category growth in H1FY27 |
| European business growth | 45% YoY |
| Other Operating Income | ₹42 cr, -81% YoY from ₹216 cr in Q2FY26 |
| H1FY27 U.S. revenue | $683 mn (per an analyst's math) |
| Implied H2FY27 U.S. quarterly run rate | ~$230 mn to hit guidance midpoint (per an analyst's math) |
| Apixaban brand market size | $10 bn+ |
| Capital deployment capacity | Up to ~₹20,000 cr (2x EBITDA debt threshold plus balance sheet cash) |
| India products launched in H1FY27 | 12; plan ~20 for full year FY27 |